Staphylococcus aureus: bacteriophage and uses thereof
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberIntralytixIntralytixIntralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Publication Number
US-7745194-B2
Publication Date
2010-06-29
Expiration Date
Abstract
The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.
Core Innovation
The invention relates to isolated bacteriophages SAML-4, SAML-150, and SATA-8505 deposited under ATCC accession Nos. PTA-9474, PTA-9475, and PTA-9476, respectively, that have lytic activity against Staphylococcus aureus strains, including MRSA/MDRSA. The disclosed scope includes isolated bacteriophage, deposited bacteriophage, progeny, derivatives, recombinant bacteriophages, and lytic enzymes.
The document states that the bacteriophages are screened for lytic specificity across Staphylococcus aureus strains and characterized by RFLP profiling. The disclosed profiles and specificity characterization support identification and characterization of the deposited bacteriophages and related progeny.
The invention further provides bacteriophage compositions and uses for controlling colonization and contamination in food, food-processing equipment, animal and human environments, and veterinary environments. The document also describes preventing or treating diseases associated with Staphylococcus aureus, food preservation, environmental control and biofilm prevention, mammalian prophylaxis and treatment, and vaccine/bacterin preparation.
In addition, the document describes detection concepts using phage/reporter systems and detection assays that incorporate adenosine kinase, adenosine triphosphate, and AK release, including reporter bacteriophage systems such as luxAB. Overall, the invention combines deposited lytic bacteriophages with compositions, prophylaxis and treatment concepts, and detection assays directed to Staphylococcus aureus.
Claims Coverage
The partial content provides two independent claims. The inventive features center on specific isolated deposited bacteriophages with lytic activity against Staphylococcus aureus strains and isolated progeny retaining the same phenotypic and lytic activity characteristics.
Deposited isolated bacteriophage with lytic activity against Staphylococcus aureus strains
An isolated bacteriophage SAML-4, SAML-150, or SATA-8505 deposited under ATCC accession Nos. PTA-9474, PTA-9475, and PTA-9476, respectively, wherein the bacteriophage has lytic activity against Staphylococcus aureus strains.
Isolated progeny with same phenotypic characteristics and lytic activity against Staphylococcus aureus strains
Isolated progeny of the bacteriophage SAML-4, SAML-150, or SATA-8505, wherein the progeny have the same phenotypic characteristics and the same lytic activity against Staphylococcus aureus strains as the bacteriophage.
Across the independent claims, the claim coverage is directed to specific deposited isolated bacteriophages SAML-4, SAML-150, and SATA-8505 having lytic activity against Staphylococcus aureus strains, and to isolated progeny retaining the same phenotypic characteristics and lytic activity.
Stated Advantages
Provides lytic activity against Staphylococcus aureus strains, including MRSA/MDRSA.
Enables control of colonization and contamination in food, food-processing equipment, animal and human environments, and veterinary environments.
Supports preventing or treating diseases associated with Staphylococcus aureus.
Enables food preservation and environmental control including biofilm prevention.
Supports mammalian prophylaxis and treatment concepts.
Supports vaccine/bacterin preparation concepts.
Supports detection assays using phage/reporter systems and ATP/AK release.
Documented Applications
Food preservation.
Environmental control and biofilm prevention.
Control of colonization and contamination in food-processing equipment.
Control of colonization and contamination in animal and human environments.
Control of colonization and contamination in veterinary environments.
Mammalian prophylaxis and treatment.
Vaccine/bacterin preparation.
Detection assays using phage/reporter systems, including luciferase reporter bacteriophage (luxAB) and detection involving adenosine kinase and adenosine triphosphate.
Interested in licensing this patent?